![Kendall Mohler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kendall Mohler
Corporate Officer/Principal at
ALSP ORCHID ACQUISITION CORPORATION I
Profile
Kendall M.
Mohler is the founder of Emergent Product Development Seattle, which was founded in 1999.
He held the title of Senior Vice President-Research & Development from 1999 to 2010.
Currently, he is the Managing Director & Chief Development Officer at Accelerator Services Corp.
He is also a Director at Neuvogen, Inc., CSO and SVP at Emergent Product Development Seattle, and Chief Development Officer at ALSP Orchid Acquisition Corp.
I.
Dr. Mohler's former jobs include Vice President-Biological Sciences at Immunex Corp.
from 2001 to 2002, Chief Scientific Officer at ZetaRx Biosciences, Inc., and Senior Vice President-Research at Juno Therapeutics, Inc. from 2015 to 2017.
Dr. Mohler received a doctorate from The University of Texas at Austin and an undergraduate degree from the University of Kansas.
Kendall Mohler active positions
| Companies | Position | Start |
|---|---|---|
| ALSP ORCHID ACQUISITION CORPORATION I | Corporate Officer/Principal | - |
Accelerator Services Corp
 Accelerator Services Corp Investment ManagersFinance Accelerator Services invests in companies located in the United States. The firm focuses on the healthcare sector. It provides financing for early stage capital requirements. | Corporate Officer/Principal | 2017-09-30 |
Neuvogen, Inc.
 Neuvogen, Inc. BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Director/Board Member | - |
Emergent Product Development Seattle
 Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Discovers and develops biopharmaceutical products | Private Equity Investor | - |
Former positions of Kendall Mohler
| Companies | Position | End |
|---|---|---|
| JUNO THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 2017-03-31 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Manufactures, markets, and researches therapeutic products | Corporate Officer/Principal | 2001-12-31 |
ZetaRx Biosciences, Inc.
 ZetaRx Biosciences, Inc. BiotechnologyHealth Technology develops therapies for the treatment of cancers and other diseases | Chief Tech/Sci/R&D Officer | - |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Discovers and develops biopharmaceutical products | Founder | - |
Training of Kendall Mohler
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
77
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Manufactures, markets, and researches therapeutic products | Health Technology |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Discovers and develops biopharmaceutical products | Health Technology |
ZetaRx Biosciences, Inc.
ZetaRx Biosciences, Inc. BiotechnologyHealth Technology develops therapies for the treatment of cancers and other diseases | Health Technology |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services invests in companies located in the United States. The firm focuses on the healthcare sector. It provides financing for early stage capital requirements. | Finance |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Neuvogen, Inc.
Neuvogen, Inc. BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Health Technology |
ALSP Orchid Acquisition Corp. I
 ALSP Orchid Acquisition Corp. I Financial ConglomeratesFinance Operates as a blank check company | Finance |
- Stock Market
- Insiders
- Kendall Mohler
